GRAIL INC (GRAL) Stock Price & Overview
NASDAQ:GRAL • US3847471014
Current stock price
The current stock price of GRAL is 54.99 USD. Today GRAL is up by 2.59%. In the past month the price increased by 6.16%. In the past year, price increased by 147.15%.
GRAL Key Statistics
- Market Cap
- 2.256B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.17
- Dividend Yield
- N/A
GRAL Stock Performance
GRAL Stock Chart
GRAL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GRAL. When comparing the yearly performance of all stocks, GRAL is one of the better performing stocks in the market, outperforming 90.22% of all stocks.
GRAL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GRAL. GRAL has a great financial health rating, but its profitability evaluates not so good.
GRAL Earnings
On February 19, 2026 GRAL reported an EPS of -2.44 and a revenue of 43.60M. The company beat EPS expectations (11.6% surprise) and missed revenue expectations (-2.15% surprise).
GRAL Forecast & Estimates
12 analysts have analysed GRAL and the average price target is 85.07 USD. This implies a price increase of 54.7% is expected in the next year compared to the current price of 54.99.
For the next year, analysts expect an EPS growth of -0.16% and a revenue growth 22.9% for GRAL
GRAL Groups
Sector & Classification
GRAL Financial Highlights
Over the last trailing twelve months GRAL reported a non-GAAP Earnings per Share(EPS) of -11.17. The EPS increased by 83.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.97% | ||
| ROE | -15.84% | ||
| Debt/Equity | 0 |
GRAL Ownership
GRAL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRAL
Company Profile
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 910 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Company Info
IPO: 2024-06-12
GRAIL INC
1525 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 910
Phone: 13026587581
GRAIL INC / GRAL FAQ
Can you describe the business of GRAIL INC?
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 910 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
What is the stock price of GRAIL INC today?
The current stock price of GRAL is 54.99 USD. The price increased by 2.59% in the last trading session.
What is the dividend status of GRAIL INC?
GRAL does not pay a dividend.
What is the ChartMill rating of GRAIL INC stock?
GRAL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for GRAL stock?
The Revenue of GRAIL INC (GRAL) is expected to grow by 22.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for GRAIL INC?
GRAIL INC (GRAL) will report earnings on 2026-05-11.